"Pharmacogenomics at Mayo Clinic: The Intersection of Patient Care and Research"
PRECISION MEDICINE SEMINAR SERIES
February 1, 2019 | 2:00 to 3:00 p.m. | 5-125 Moos Tower (TC); 302 Heller Hall (Duluth via ITV)
Dr. Suzette Bielinski received a BS at the College of Saint Catherine, and a Master’s degree in Education and PhD in Epidemiology with a minor in Human Genetics at the University of Minnesota. She was a NIH Cardiovascular Disease Genetic Pre-doctoral and Post-doctoral Fellow at the University of Minnesota and joined Mayo Clinic in 2008. Dr. Bielinski’s research program focuses on the molecular biomarkers of cardiovascular disease with funding from the National Institutes of Health and the Mayo Foundation. Dr. Bielinski has been at the forefront of Mayo Clinic’s interactions with several important cardiovascular cohort studies and consortia including the Atherosclerosis Risk in Communities (ARIC), Coronary Artery Risk Development in Young Adults (CARDIA) Study, and Multi-Ethnic Study of Atherosclerosis (MESA). She is a leader of the Mayo Clinic’s RIGHT Protocol Study that is designed to implement pharmacogenomic sequence data into clinical systems to improve patient outcomes. The RIGHT Protocol is a collaboration between the Mayo Clinic Centers for Individualized Medicine and Science of Health Care Delivery. Notably, this collaboration, with over 11,000 participants, is one of the largest and most extensive preemptive pharmacogenomic studies in the world.